Michael Siegel, MD
Ophthalmology · Southfield, MINPI 1811217912
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 38.7% of the total. Reporting peaked in 2022 at $7,620 and has fallen 60.9% since, to $2,982 in 2025. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $73.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$6K
- AbbVie$2K
- Sight Sciences, Inc.$2K
- Beaver-visitec International, Inc.$1K
- Alcon$1K
- NEW World Medical,inc.$952
- plus $2K from 16 others
What the payments were for
- Consulting fees$1,4009%
- Speaking & faculty fees$5,93839%
- Food & beverage$7,99852%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 2 | $5,938 |
| AbbVie(2 entities) | 60 | $1,993 |
| Sight Sciences, Inc. | 32 | $1,742 |
| Beaver-visitec International, Inc. | 2 | $1,414 |
| Alcon | 32 | $1,308 |
| NEW World Medical,inc. | 19 | $952 |
| Nova Eye, Inc. | 1 | $400 |
| Glaukos Corporation | 7 | $364 |
| LEO Pharma Inc. | 19 | $336 |
| Carl Zeiss Meditec USA, Inc. | 2 | $227 |
| Novartis | 3 | $162 |
| Aerie Pharmaceuticals, Inc. | 10 | $155 |
| Thea Pharma Inc. | 4 | $82 |
| Sun Pharmaceutical Industries Inc. | 3 | $63 |
| Ivantis, Inc | 3 | $61 |
| Johnson & Johnson | 2 | $35 |
| Akorn, Inc. | 2 | $34 |
| Akorn Operating Company LLC | 1 | $18 |
| EPI Health, LLC | 1 | $18 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $17 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$5,938
- OMNI(R) SURGICAL SYSTEM (US)$1,141
- XEN GLAUCOMA TREATMENT SYSTEM$436
- SION SURGICAL INSTRUMENT$370
- Hydrus Microstent$364
- XEN$251
- Centurion$241
- iDoseTR$186
- Ahmed Glaucoma Valve$129
- Kahook Dual Blade$129
- Humphrey HFA$128
- Clareon$107
How this compares
$15,350 in reported general payments places this provider in the 95th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 178 | $82,173 |
| RocklatanNetarsudil Mesylat/Latanoprost | 99 | $42,723 |
| Latanoprost | 1,916 | $37,057 |
| Prednisolone Acetate | 554 | $31,344 |
| CombiganBrimonidine Tartrate/Timolol | 85 | $30,476 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 131 | $29,977 |
| RhopressaNetarsudil Mesylate | 57 | $26,751 |
| Brinzolamide | 96 | $24,462 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 789 | $22,379 |
| Timolol Maleate | 837 | $22,363 |
| Brimonidine Tartrate | 676 | $19,896 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 47 | $15,705 |
| RestasisCyclosporine | 18 | $14,607 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 60 | $13,976 |
| VyzultaLatanoprostene Bunod | 36 | $13,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis | $1,993 | $127,255281 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $155 | $69,474156 claims |
| AlconSimbrinza | $1,308 | $15,70547 claims |
| Akorn, Inc.Zioptan | $34 | $4,64719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Southfield
- Victoria WilliamsSouthfield$59K
- Joel MillerSouthfield$8K
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Jason MillerAnn Arbor$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.